This content is from: Patents

PTAB 4 Years In: Biotech/pharma’s share of AIA trials increases

Biotechnology/pharmaceutical companies were slow to use the Patent Trial and Appeal Board. This is now changing, though this patent type has lower institution and invalidation rates

Get Free Access to read more …

To read the full article, activate your free trial.

Get Free Access
  • Unlimited articles for one week
  • No commitments; no payment details required
  • Featuring IP strategy, copyright, patents, trademark and more!

Are you a Managing IP subscriber? Simply login here.

Related